Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mineralys Therapeutics, Inc. (MLYS)
NASDAQ:MLYS
RESEARCH TOOLSreports
Holding MLYS?
Track your performance easily
Earnings Data
Report Date
Mar 12, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$1.08Last Year’s EPS
-$0.61Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 11, 2024
|% Change Since: -20.71%
|Next Earnings Date:Mar 12, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view with significant progress in clinical trials and financial stability but was offset by increased R&D expenses and a larger net loss. The company's advancement in clinical trial enrollment and diverse participant demographics are positive, but the financials indicate some challenges.Company Guidance
During the Mineralys Q3 2024 earnings call, the company provided several forward-looking metrics and guidance related to their clinical programs and financial outlook. The pivotal Advance-HTN trial, evaluating lorundrostat in hypertension, has completed enrollment with subjects randomized across three arms: placebo, lorundrostat 50 mg once daily, and lorundrostat titrated up to 100 mg. Key subject demographics include over 66% with a BMI ≥30, 40% women, and 50% Black or African American participants. The primary endpoint is the change in 24-hour ambulatory systolic blood pressure at week 12. Top-line data for this trial is expected in March 2025. For the Launch-HTN trial, enrollment was completed ahead of schedule, with results anticipated in the first half of 2025. Financially, the company ended the quarter with $263.6 million in cash, cash equivalents, and investments, sufficient to fund operations into 2026. R&D expenses rose to $54 million, largely due to increased costs associated with the lorundrostat pivotal program.Completion of Enrollment in Key Clinical Trials
Mineralys completed enrollment in both the Advance HTN and Launch HTN trials ahead of schedule, with top-line data expected in the first half of 2025.
Diverse Participant Demographics
In the Advance HTN trial, more than 66% of subjects have a BMI equal to or greater than 30, over 40% are women, and more than 50% are Black or African American, ensuring a diverse sample for the study.
Sufficient Financial Resources
The company ended the quarter with $263.6 million in cash, cash equivalents, and investments, which is projected to fund operations into 2026.
---
MLYS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MLYS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 11, 2024 | $14.92 | $13.38 | -10.32% |
| Aug 13, 2024 | $11.83 | $9.13 | -22.82% |
| May 09, 2024 | $14.65 | $14.27 | -2.59% |
| Mar 21, 2024 | $13.39 | $13.09 | -2.24% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Mineralys Therapeutics, Inc. (MLYS) report earnings?
Mineralys Therapeutics, Inc. (MLYS) is schdueled to report earning on Mar 12, 2025, TBA Not Confirmed.
What is Mineralys Therapeutics, Inc. (MLYS) earnings time?
Mineralys Therapeutics, Inc. (MLYS) earnings time is at Mar 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MLYS EPS forecast?
MLYS EPS forecast for the fiscal quarter 2024 (Q4) is -$1.08.
---